JP2023549441A5 - - Google Patents

Info

Publication number
JP2023549441A5
JP2023549441A5 JP2023552376A JP2023552376A JP2023549441A5 JP 2023549441 A5 JP2023549441 A5 JP 2023549441A5 JP 2023552376 A JP2023552376 A JP 2023552376A JP 2023552376 A JP2023552376 A JP 2023552376A JP 2023549441 A5 JP2023549441 A5 JP 2023549441A5
Authority
JP
Japan
Prior art keywords
chimeric antigen
antigen receptor
seq
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023552376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549441A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2021/051374 external-priority patent/WO2022104424A1/en
Publication of JP2023549441A publication Critical patent/JP2023549441A/ja
Publication of JP2023549441A5 publication Critical patent/JP2023549441A5/ja
Pending legal-status Critical Current

Links

JP2023552376A 2020-11-18 2021-11-18 キメラ抗原受容体t細胞および方法 Pending JP2023549441A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020904256 2020-11-18
AU2020904256A AU2020904256A0 (en) 2020-11-18 Chimeric Antigen Receptor T Cell and Method
PCT/AU2021/051374 WO2022104424A1 (en) 2020-11-18 2021-11-18 Chimeric antigen receptor t cell and method

Publications (2)

Publication Number Publication Date
JP2023549441A JP2023549441A (ja) 2023-11-24
JP2023549441A5 true JP2023549441A5 (cg-RX-API-DMAC10.html) 2024-11-25

Family

ID=81707894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023552376A Pending JP2023549441A (ja) 2020-11-18 2021-11-18 キメラ抗原受容体t細胞および方法

Country Status (9)

Country Link
US (1) US20240033356A1 (cg-RX-API-DMAC10.html)
EP (1) EP4247856A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023549441A (cg-RX-API-DMAC10.html)
KR (1) KR20230118850A (cg-RX-API-DMAC10.html)
CN (1) CN116829161A (cg-RX-API-DMAC10.html)
AU (1) AU2021382173A1 (cg-RX-API-DMAC10.html)
CA (1) CA3202371A1 (cg-RX-API-DMAC10.html)
IL (1) IL303015A (cg-RX-API-DMAC10.html)
WO (1) WO2022104424A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025261427A1 (zh) * 2024-06-20 2025-12-26 启光德健医药科技(苏州)有限公司 用于评估抗体免疫激动剂偶联物产生ada的方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2884999T (lt) * 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
CA2944649C (en) * 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
US10745487B2 (en) * 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
WO2018064076A1 (en) * 2016-09-27 2018-04-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
US20200114017A1 (en) * 2017-06-16 2020-04-16 Bionomics Limited Antibody drug conjugates that bind lgr5
DK3688032T3 (da) * 2017-09-26 2025-12-15 Cero Therapeutics Holdings Inc Kimære engulfment-receptormolekyler og anvendelsesfremgangsmåder
RU2020135107A (ru) * 2018-03-28 2022-04-29 Серо Терапьютикс, Инк. Клеточные иммунотерапевтические композиции и их применения
MX2020010235A (es) * 2018-03-28 2020-10-28 Cero Therapeutics Inc Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.

Similar Documents

Publication Publication Date Title
US12343379B2 (en) Interleukin-18 variants and methods of use
AU2019218989B2 (en) Chimeric antigen receptors targeting the tumor microenvironment
KR102520550B1 (ko) Cd19 및 cd20을 표적화하는 조합된 키메라 항원 수용체 및 그의 적용
US10774151B2 (en) Anti-human 4-1BB antibodies and uses thereof
JP7061235B2 (ja) 抗cld18a2ナノ抗体及びその応用
US20260078166A1 (en) Anti-dll3 chimeric antigen receptors and uses thereof
JP2024125370A (ja) クローディン18.2結合部分およびその利用
JP2024023318A (ja) 二重特異性抗体の組成物及びその使用方法
US20240374679A1 (en) Interleukin-18 mimics and methods of use
US12600776B2 (en) Anti-L1CAM antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same
JP2022542543A5 (cg-RX-API-DMAC10.html)
JP2021121201A (ja) 前立腺特異幹細胞抗原に対する抗体およびその使用
JP2018521008A (ja) 腫瘍形成を処置するための治療用組成物および治療方法
CN115989033B (zh) 用于使用cd70特异性融合蛋白进行tcr重编程的组合物和方法
CN109651511A (zh) 一种靶向bcma的嵌合抗原受体及其应用
JP2022501361A (ja) バリアントcd80融合タンパク質および関連構築物の方法および使用
CN112689642A (zh) 具有各种不同的构建物优化的t细胞抗原偶联物
CN113825772A (zh) 抗her2亲合体及将其用作开关分子的可切换嵌合抗原受体
JP2023552724A (ja) キメラ受容体及びその使用方法
JP2022514815A (ja) CDR1領域に突然変異したヒト化CD19 scFvを有するCAR-T細胞
EP4630041A1 (en) A kit for use in the treatment of hematological cancer
WO2024231348A1 (en) Slc4a4/nbce1 inhibitors
EA047760B1 (ru) Группы, связывающие клаудин 18.2, и их использование
NZ750420A (en) Antibody for anti-claudin 18a2 and use thereof